BACKGROUND: We have previously reported operational tolerance in patients receiving human leukocyte antigen-mismatched combined kidney and bone marrow transplantation (CKBMT). We now report on transient multilineage hematopoietic chimerism and lymphocyte recovery in five patients receiving a modified CKBMT protocol and evidence for early donor-specific unresponsiveness in one of these patients. METHODS: Five patients with end-stage renal disease received CKBMT from human leukocyte antigen-mismatched, haploidentical living-related donors after modified nonmyeloablative conditioning. Polychromatic flow cytometry was used to assess multilineage chimerism and lymphocyte recovery posttransplant. Limiting dilution analysis was used to assess helper T-lymphocyte reactivity to donor antigens. RESULTS: Transient multilineage mixed chimerism was observed in all patients, but chimerism became undetectable by 2 weeks post-CKBMT. A marked decrease in T- and B-lymphocyte counts immediately after transplant was followed by gradual recovery. Initially, recovering T cells were depleted of CD45RA+/CD45RO(-) "naïve-like" cells, which have shown strong recovery in two patients, and CD4:CD8 ratios increased immediately after transplant but then declined markedly. Natural killer cells were enriched in the peripheral blood of all patients after transplant.For subject 2, a pretransplant limiting dilution assay revealed T helper cells recognizing both donor and third-party peripheral blood mononuclear cells. However, the antidonor response was undetectable by day 24, whereas third-party reactivity persisted. CONCLUSION: These results characterize the transient multilineage mixed hematopoietic chimerism and recovery of lymphocyte subsets in patients receiving a modified CKBMT protocol. The observations are relevant to the mechanisms of donor-specific tolerance in this patient group.
BACKGROUND: We have previously reported operational tolerance in patients receiving human leukocyte antigen-mismatched combined kidney and bone marrow transplantation (CKBMT). We now report on transient multilineage hematopoietic chimerism and lymphocyte recovery in five patients receiving a modified CKBMT protocol and evidence for early donor-specific unresponsiveness in one of these patients. METHODS: Five patients with end-stage renal disease received CKBMT from human leukocyte antigen-mismatched, haploidentical living-related donors after modified nonmyeloablative conditioning. Polychromatic flow cytometry was used to assess multilineage chimerism and lymphocyte recovery posttransplant. Limiting dilution analysis was used to assess helper T-lymphocyte reactivity to donor antigens. RESULTS: Transient multilineage mixed chimerism was observed in all patients, but chimerism became undetectable by 2 weeks post-CKBMT. A marked decrease in T- and B-lymphocyte counts immediately after transplant was followed by gradual recovery. Initially, recovering T cells were depleted of CD45RA+/CD45RO(-) "naïve-like" cells, which have shown strong recovery in two patients, and CD4:CD8 ratios increased immediately after transplant but then declined markedly. Natural killer cells were enriched in the peripheral blood of all patients after transplant.For subject 2, a pretransplant limiting dilution assay revealed T helper cells recognizing both donor and third-party peripheral blood mononuclear cells. However, the antidonor response was undetectable by day 24, whereas third-party reactivity persisted. CONCLUSION: These results characterize the transient multilineage mixed hematopoietic chimerism and recovery of lymphocyte subsets in patients receiving a modified CKBMT protocol. The observations are relevant to the mechanisms of donor-specific tolerance in this patient group.
Authors: T Kawai; A Poncelet; D H Sachs; S Mauiyyedi; S Boskovic; S L Wee; D S Ko; A Bartholomew; M Kimikawa; H Z Hong; G Abrahamian; R B Colvin; A B Cosimi Journal: Transplantation Date: 1999-12-15 Impact factor: 4.939
Authors: Brian A Rabinovich; Jennifer Li; John Shannon; Rose Hurren; Jan Chalupny; David Cosman; Richard G Miller Journal: J Immunol Date: 2003-04-01 Impact factor: 5.422
Authors: Annette B Kraus; Juanita Shaffer; Han Chong Toh; Frederic Preffer; David Dombkowski; Susan Saidman; Christine Colby; Richard George; Steven McAfee; Robert Sackstein; Bimalangsu Dey; Thomas R Spitzer; Megan Sykes Journal: Exp Hematol Date: 2003-07 Impact factor: 3.084
Authors: Christian Koenecke; Juanita Shaffer; Stephen I Alexander; Frederic Preffer; David Dombkowski; Susan L Saidman; Bimalanghu Dey; Steven McAfee; Thomas R Spitzer; Megan Sykes Journal: Exp Hematol Date: 2003-10 Impact factor: 3.084
Authors: S K Ramakrishnan; A Page; A B Farris; K Singh; F Leopardi; K Hamby; S Sen; A Polnett; T Deane; M Song; L Stempora; E Strobert; A D Kirk; C P Larsen; L S Kean Journal: Am J Transplant Date: 2012-05-29 Impact factor: 8.086
Authors: Daniel R Getts; Sushma Shankar; Emily M L Chastain; Aaron Martin; Meghann Teague Getts; Kathryn Wood; Stephen D Miller Journal: Immunotherapy Date: 2011-07 Impact factor: 4.196
Authors: Anil Dangi; Shuangjin Yu; Frances T Lee; Melanie Burnette; Jiao-Jing Wang; Yashpal S Kanwar; Zheng J Zhang; Michael Abecassis; Edward B Thorp; Xunrong Luo Journal: Kidney Int Date: 2020-02-21 Impact factor: 10.612
Authors: A Tena; J Kurtz; D A Leonard; J R Dobrinsky; S L Terlouw; N Mtango; J Verstegen; S Germana; C Mallard; J S Arn; D H Sachs; R J Hawley Journal: Am J Transplant Date: 2014-10-02 Impact factor: 8.086
Authors: T Kawai; D H Sachs; B Sprangers; T R Spitzer; S L Saidman; E Zorn; N Tolkoff-Rubin; F Preffer; K Crisalli; B Gao; W Wong; H Morris; S A LoCascio; P Sayre; B Shonts; W W Williams; R-N Smith; R B Colvin; M Sykes; A B Cosimi Journal: Am J Transplant Date: 2014-06-05 Impact factor: 8.086